Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Cosmos Health Inc. - Common Stock (NQ:COSM)

0.4290 -0.0170 (-3.81%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 16, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 186,519
Open 0.4426
Bid (Size) 0.4201 (10)
Ask (Size) 0.4275 (40)
Prev. Close 0.4460
Today's Range 0.4202 - 0.4490
52wk Range 0.2801 - 1.580
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
RETRANSMISSION – Cosmos Health Reports Q1 2025 Results: Adjusted Profitability Achieved as Gross Profit Rises 54% to $2.05M; Operating Cash Burn Down 95%, or $3.2M, to $0.19M; Approaching Cash Flow Breakeven
From Cosmos Health Inc.
Via GlobeNewswire
Cosmos Health Reports Q1 2025 Results: Adjusted Profitability Achieved as Gross Profit Rises 54% to $2.05M; Operating Cash Burn Down 95%, or $3.2M, to $0.19M; Approaching Cash Flow Breakeven
From Cosmos Health Inc.
Via GlobeNewswire

Performance

YTD
-37.5%
-37.5%
1 Month
+24.4%
+24.4%
3 Month
-30.7%
-30.7%
6 Month
-31.9%
-31.9%
1 Year
-38.7%
-38.7%

More News

Read More
Cosmos Health Secures Follow-Up Order from Pharmalink for 80,000 Sky Premium Life Units in the UAE; Initial 130,000-unit Order Sold Out, Advancing 5-Year Goal of Over 3 Million Units
From Cosmos Health Inc.
Via GlobeNewswire
Cosmos Health Receives Additional 180-Day Compliance Period from Nasdaq
From Cosmos Health Inc.
Via GlobeNewswire
Cosmos Health CEO Greg Siokas Acquires 1,466,764 Shares Valued at $526,000 Over the Past Week; 2,777,469 Shares Acquired Over the Past Five Months for $1,325,000
From Cosmos Health Inc.
Via GlobeNewswire
Cosmos Health Reports Full-Year 2024 Results: Revenue Increases 2% to $54.43 Million While Operating Expenses Decline 24.2% to $19.86 Million
From Cosmos Health Inc.
Via GlobeNewswire
Cosmos Health Further Expands Facility Upgrades Program at Cana Laboratories and Signs 5-Year Contract Manufacturing Agreement with Pharmex for 1.5 Million Bottles of the Antiseptic Drug AMBITASOL 1L
From Cosmos Health Inc.
Via GlobeNewswire
Cosmos Health Announces Launch Of Food Supplement Brand In Albania: Retail Sentiment Improves
Via Stocktwits
Topics Economy Government
Exposures Interest Rates Political
Cosmos Health Launches Sky Premium Life in Albania through Partnership with Pharma Cell; Secures Initial $300,000 Order
From Cosmos Health Inc.
Via GlobeNewswire
Cosmos Health Expands Sky Premium Life Nutraceuticals Brand with 60 New SKUs as Global Growth Accelerates
Via ACCESS Newswire
EXCLUSIVE: Virax Biolabs Says Its Tech Fits RFK Jr.'s HHS Goals On Vaccine Transparency
Via Benzinga
Cosmos Health Announces It will not Proceed with an Offering Under Its Form S-1
Via ACCESS Newswire
Cosmos Health Enters Final Development Phase of CCX0722 Weight Management Solution; Expected Product Launch in Q1 or Q2 2026, Gaining Access to Over $142 Billion Market
Via ACCESS Newswire
Cosmos Health Advances Cancer Treatment Innovation with Two New AI-Driven Patent Filings for Gliomas and Hematologic Malignancies; $25 Billion+ Global Market
Via ACCESS Newswire
Cosmos Health Strengthens Management Team with the Appointment of Veteran Executive Dimitris Moraitis as Vice President of Strategy & Operations
Via ACCESS Newswire
Cosmos Health Pockets 10-Year Manufacturing Deal With Provident Pharmaceuticals
Via Benzinga
Cosmos Health Secures 10-Year Long-Term Contract Manufacturing Order from Provident Pharmaceuticals for 4 Additional Products, Totaling 8 Million Packs, Significantly Expanding High-Margin Revenue Backlog and Cash Flow Visibility
Via ACCESS Newswire
Cosmos Health Receives $578,460 Initial Purchase Order from Al Rabwa International for Sky Premium Life Food Supplements in Qatar
Via ACCESS Newswire
Cosmos Health Files New AI-Driven Patent Application for Multiple Sclerosis Treatment, Targeting $25 Billion+ Global Market
Via ACCESS Newswire
Cosmos Health Secures Bond Loan from European Bank on Very Competitive Terms, with Option to Upsize to Support Growth and Achieve Positive Operating Cash Flow
Via ACCESS Newswire
Cosmos Health Submits Patent Application for Allergic Inflammation Therapy by Leveraging AI Drug Repurposing; Allergy Treatment Market Valued at $23.5 Billion
Via ACCESS Newswire
Cosmos Health Signs Expanded Exclusive Distribution Agreement with Virax Biolabs for Avian Influenza Virus PCR Kits in Saudi Arabia, the UAE, Qatar, and Kuwait
Via ACCESS Newswire
Cosmos Health Secures Two WIPO-Patented Anticancer Drugs for Prostate, Ovarian, and Colorectal Cancers, Valued at Over $24.5 Million
Via ACCESS Newswire
Cosmos Health CEO Greg Siokas Acquires a Total of 647,809 Shares Valued at $425,000 Over the Past 32 Days
Via ACCESS Newswire
Cosmos Health Secures Exclusive Distribution Agreement with Virax Biolabs for Avian Influenza Virus PCR Kits in Greece and Cyprus, with Additional Rights in Select European and GCC Countries
Via ACCESSWIRE

Frequently Asked Questions

Is Cosmos Health Inc. - Common Stock publicly traded?
Yes, Cosmos Health Inc. - Common Stock is publicly traded.
What exchange does Cosmos Health Inc. - Common Stock trade on?
Cosmos Health Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Cosmos Health Inc. - Common Stock?
The ticker symbol for Cosmos Health Inc. - Common Stock is COSM on the Nasdaq Stock Market
What is the current price of Cosmos Health Inc. - Common Stock?
The current price of Cosmos Health Inc. - Common Stock is 0.4290
When was Cosmos Health Inc. - Common Stock last traded?
The last trade of Cosmos Health Inc. - Common Stock was at 05/16/25 04:00 PM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.